CF
HZNP

Cantor Fitzgerald’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Cantor Fitzgerald’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-19,665
Closed -$2.28M – 631
2023
Q3 		$2.28M Sell
19,665
-19,875
-50% -$2.14M 0.06% 216
2023
Q2 		$4.07M Buy
39,540
+13,580
+52% +$1.43M 0.09% 208
2023
Q1 		$2.83M Buy
+25,960
New +$2.87M 0.06% 285

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cantor Fitzgerald's HZNP Position: Q4 2023 in Review

Cantor Fitzgerald sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 19,665 shares — an estimated $2.28M sold.

Cantor Fitzgerald first reported a position in HZNP in Q1 2023 and held it in 3 quarters. The position peaked at $4.07M in Q2 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Cantor Fitzgerald reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Cantor Fitzgerald sold 19,665 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $2.28M.
  • Cantor Fitzgerald first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 3 quarters.
  • Cantor Fitzgerald's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4.07M in Q2 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Cantor Fitzgerald's 13F filing for Q4 2023, filed 14 Feb 2024.